Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.44 USD | -0.91% | -6.74% | +65.25% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.25% | 2.69B | |
+4.08% | 111B | |
+11.45% | 105B | |
-12.86% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.30% | 16.96B | |
+2.94% | 13.7B | |
+36.62% | 12.45B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- BMO Capital Adjusts Price Target on Merus to $49 From $47, Maintains Outperform Rating